483 articles with Evotec AG
Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec's DNA damage response ("DDR") portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers.
Evotec SE announced that the strategic transaction to acquire Just Biotherapeutics, signed on 20 May 2019, has been completed.
Nosopharm and Evotec SE announce their partnership aimed at advancing Nosopharm’s lead candidate, NOSO-502, to the clinical stage, as well as developing a second-generation Odilorhabdin drug candidate.
Evotec SE announced that the Company successfully issued a Schuldschein of EUR 250 m on the capital market.
Interest in large-scale Linear DNA for nucleic acid-based therapies continues to rise
Sensyne Health, Evotec, OSI and the University of Oxford create new partnership called LAB10x to accelerate data-driven drug discovery powered by AI
LAB10x aims to accelerate the commercialisation of the next generation of digital therapeutics and data-driven drug discovery from clinical artificial intelligence research and digital health innovations at the University of Oxford
The technologies developed by LAB10x will be applied to generate and analyze “anonymized” patient data sets to improve patient outcomes and accelerate medical research and pharmaceutical R&D.
Evotec SE announced that its shareholders approved all proposals the Company's Management put to vote at the Company's Annual General Meeting 2019 with very strong supporting majorities.
“We are honored to join with The Bill & Melinda Gates Foundation to fight tuberculosis, one of the world’s most deadly infectious diseases,” stated Werner Lanthaler, Evotec’s chief executive officer.
Evotec SE announced that the company has entered into a five-year partnership with the Bill & Melinda Gates Foundation to discover new treatment regimens that better address tuberculosis ("TB"), a severe global health burden and one of the leading causes of death due to infectious diseases worldwide.
Evotec SE announced that its strategic alliance with Celgene Corporation has been expanded to include a new cell type triggering a payment of $ 9.0 m to Evotec.
Evotec SE announced today the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio") based in Seattle, WA, USA for up to US$ 90 m (approx. EUR 81 m; EUR/$ fx rate of 1.117) including potential performance-based earn-out components expected within the next three years.
Evotec SE announced the signing of a definitive agreement under which Evotec will acquire Just Biotherapeutics, Inc. ("Just.Bio"), for up to $ 90 m including potential performance-based earn-out components expected within the next three years.
Evotec SE announced today that its management will be presenting at and attending the following upcoming conferences:
Evotec SE reported financial results and corporate updates for the first quarter of 2019.
Evotec SE will report its financial results for the first quarter of 2019 on Tuesday, 14 May 2019.
Eur 140 m bridge loan was drawn to secure evotec's value chain expansion by successful acquisition of aptuit in august 2017
Evotec And Indivumed Announce Strategic Drug Discovery Collaboration On Precision Medicine For Colorectal Cancer
The collaboration leverages indivumed's true multi-omics cancer database "Indivutype" and evotec's drug discovery platforms to identify new therapeutics for colorectal cancer
Evotec SE announced that it has completed its conversion into a company under European law with its registration in the commercial register of the District Court of Hamburg.
Evotec And The Mark Foundation For Cancer Research Announce Strategic Collaboration In Immuno-oncology
Evotec and the mark foundation form first collaboration together to advance oncology assets based on evotec's new allosteric inhibitor platform "Targetallomod"